Connor, Clark & Lunn Investment Management Ltd. Alkermes Plc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$26 Billion
Q2 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Alkermes Plc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 75,339 shares of ALKS stock, worth $2.37 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

75,339

Previous 47,738 57.82%

Holding current value

$2.37 Million

Previous $1.58 Million 36.74%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	BUY	$26.59 - $32.65 $733,910 - $901,172	27,601 Added 57.82%	75,339 $2.16 Million
Q1 2025 May 12, 2025	BUY	$28.08 - $36.0 $1.34 Million - $1.72 Million	47,738 New	47,738 $1.58 Million
Q3 2024 Nov 08, 2024	SELL	$23.01 - $28.55 $4.02 Million - $4.99 Million	-174,742 Reduced 85.89%	28,699 $803,000
Q2 2024 Aug 09, 2024	BUY	$23.21 - $27.24 $240,548 - $282,315	10,364 Added 5.37%	203,441 $4.9 Million
Q1 2024 May 09, 2024	SELL	$26.4 - $32.56 $4.25 Million - $5.25 Million	-161,133 Reduced 45.49%	193,077 $5.23 Million
Q4 2023 Feb 09, 2024	SELL	$23.37 - $28.68 $5.43 Million - $6.66 Million	-232,382 Reduced 39.62%	354,210 $9.83 Million
Q3 2023 Nov 13, 2023	SELL	$27.17 - $31.97 $1.26 Million - $1.48 Million	-46,337 Reduced 7.32%	586,592 $16.4 Million
Q2 2023 Aug 10, 2023	SELL	$28.34 - $33.63 $166,299 - $197,340	-5,868 Reduced 0.92%	632,929 $19.8 Million
Q1 2023 May 09, 2023	SELL	$25.31 - $29.02 $17,210 - $19,733	-680 Reduced 0.11%	638,797 $18 Million
Q4 2022 Feb 10, 2023	BUY	$21.94 - $26.24 $9.81 Million - $11.7 Million	446,993 Added 232.22%	639,477 $16.7 Million
Q3 2022 Nov 10, 2022	BUY	$22.0 - $31.87 $540,188 - $782,535	24,554 Added 14.62%	192,484 $4.3 Million
Q2 2022 Aug 05, 2022	BUY	$26.4 - $30.54 $4.43 Million - $5.13 Million	167,930 New	167,930 $5 Million
Q4 2021 Feb 10, 2022	SELL	$21.47 - $32.08 $1.43 Million - $2.14 Million	-66,746 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$23.37 - $32.13 $1.56 Million - $2.14 Million	66,746 New	66,746 $2.06 Million
Q1 2021 May 13, 2021	SELL	$18.21 - $23.2 $346,463 - $441,403	-19,026 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$15.39 - $22.1 $292,810 - $420,474	19,026 New	19,026 $380,000
Q2 2020 Aug 13, 2020	SELL	$13.31 - $19.41 $3.54 Million - $5.16 Million	-265,785 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$13.06 - $21.24 $932,888 - $1.52 Million	-71,431 Reduced 21.18%	265,785 $3.83 Million
Q4 2019 Feb 12, 2020	BUY	$17.29 - $21.74 $4.3 Million - $5.4 Million	248,466 Added 279.96%	337,216 $6.88 Million
Q3 2019 Nov 13, 2019	BUY	$19.51 - $24.28 $1.73 Million - $2.15 Million	88,750 New	88,750 $1.73 Million

Others Institutions Holding ALKS

# of Institutions

393

Shares Held

176M

Call Options Held

558K

Put Options Held

427K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.18B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Alkermes Plc. Transaction History